Ihre Suche nach:
45 Ergebnis(se) in 0.02 s
-
DUKAS_119998810_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998809_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998808_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998807_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998806_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998805_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998802_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998801_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998800_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUKAS_119998799_ABA
HQ of Swissmedic, the Swiss Agency for Therapeutic Products
Headquarters of Swissmedic, the Swiss Agency for Therapeutic Products, has received a third application for approval of a coronavirus vaccine from the American biotechnology company Moderna, the agency announced on Friday. Switzerland Bern, November 18, 2020. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
Glories Francois/ABACA -
DUK10132484_027
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_026
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_025
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_024
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_023
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_022
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_021
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_020
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_019
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_018
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_017
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_016
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_015
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_014
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_013
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_012
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_011
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_010
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_009
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_008
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_007
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_006
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_005
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_004
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_003
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_002
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUK10132484_001
NEWS - EU lässt Gentherapie-Medikament Zolgensma von Novartis zu
Headquarters of the pharmaceutical giant "Novartis" in Basel, Switzerland. on May 25, 2020. "Green light for the world's most expensive drug".
Novartis has received European approval for the gene therapy Zolgensma (onasemnogene abeparvovec) for babies and children with spinal muscular atrophy (SMA) type 1. It is now available in France and should soon be available in Germany. Discussions are ongoing regarding its price. Photo by Francois Glories/ABACAPRESS.COM (FOTO: DUKAS/ABACA)
(c) Dukas -
DUKAS_15824742_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824705_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824701_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824692_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824691_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824687_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824626_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS -
DUKAS_15824616_KCS
EXCLUSIVE. Rachel Bilson strolling in Paris during Fashion Week
EXCLUSIVE
Paris, 10/03/2010
American actress Rachel Bilson enjoys a walk in the streets of Paris. She ate a croissant and banana and had to take meds or vitamin c, is she hangover?
Rachel played the perfect tourist as she took photographs of Notre Dame and tried on a hat in a souvenir shop. She is in Paris for the Fashion Week.
Pictured: Rachel Bilson
ID Number: 0220508
DUKAS/KCS